New Approach to Target-Binding Antibody Development

As biomedicine enters the era of precision medicine, target-binding antibodies have become the brightest stars on the stage of drug development. From anti-tumor PD-1 inhibitors to TNF-α blockers for autoimmune diseases, these antibody drugs that can accurately recognize and 'grasp' disease targets repeatedly rewrite treatment paradigms. However, the birth of a high-quality target-binding antibody is often accompanied by years of trial and error, exorbitant R&D investment, and the sighs of countless failed candidate drugs. Today, the launch of MatwingsVenus™ (XiaoWu™) intelligent system by Matwings Technology is opening a new intelligent path for the design of target-binding antibodies.

What are target-binding antibodies?

To understand target-binding antibodies, we first need to start with our body's immune system. When viruses, bacteria, and other 'foreign invaders' enter the body, our immune system produces a type of protein called 'antibody.' Antibodies are like 'patrolling missiles' in the body, capable of precisely recognizing and binding to these invaders, marking them for removal by immune cells, or directly blocking their pathogenic capabilities. Target-binding antibodies refer to antibodies that can specifically recognize and bind to a particular target molecule. This 'target' can be a protein on the surface of a virus (such as the spike protein of the coronavirus), a marker on the surface of cancer cells (such as PD-L1), or a cytokine involved in inflammatory responses in the body (such as TNF-α). You can think of target-binding antibodies as a specially made key, and the target as its corresponding lock. The key and lock must fit perfectly to function—binding too strongly may cause unnecessary over-inhibition of the target or reduced tissue penetration, while binding too weakly won't achieve the therapeutic effect.

Target-Binding Antibody

This is also why antibody drugs have become one of the hottest directions in the biopharmaceutical field over the past 20 years. From adalimumab (Humira) topping global drug sales for consecutive years to PD-1/PD-L1 antibodies completely changing the landscape of cancer treatment, target-binding antibodies have made significant contributions to modern medicine.

How do antibodies precisely bind to their targets?

So, how do target-binding antibodies work? The answer lies in their molecular structure. Antibodies are Y-shaped protein molecules. The two 'arms' of the Y are called antigen-binding fragments (Fab), the key regions for binding to targets; the 'tail' of the Y is called the Fc region (crystallizable fragment), responsible for interacting with immune cells.

What truly determines an antibody's binding ability are the six complementarity-determining regions (CDRs) at the tip of the Fab region — three on the heavy chain and three on the light chain. These six regions form loop structures that together create the binding interface with the target.

The binding between an antibody and its target is a precise network woven by spatial complementarity, hydrophobic packing, hydrogen bond networks, electrostatic interactions, and van der Waals forces. A good target-binding antibody usually has high affinity, high specificity, and favorable druggability.

Antibody

How widely are target-binding antibodies applied?

Nowadays, target-binding antibodies have long surpassed the single role of 'therapeutic drugs' and have permeated the entire biopharmaceutical chain. In the field of disease treatment, they cover many areas including tumor immunology, autoimmune diseases, metabolic diseases, infectious diseases, and neurodegenerative disorders. New technologies such as bispecific antibodies and antibody-drug conjugates (ADCs) further expand their range of action. In in vitro diagnostics, target-binding antibodies are the core components of ELISA kits, immunohistochemistry, and lateral flow assays. During the COVID-19 pandemic, home antigen test strips relied on a pair of high-affinity, highly specific target-binding antibodies. In addition, in basic science and early-stage drug discovery, they are used as research tools for target validation, receptor antagonism, flow sorting, and structural analysis.

Globally, the demand for various customized target-binding antibodies is extremely strong every year, while the bottleneck in development lies precisely in how to efficiently obtain ideal candidate molecules—which is exactly the part that traditional methods struggle with the most.

Applications of Target-Binding Antibodies

The challenges of targeting antibodies and Xiaowu's breakthrough

Traditional antibody development cycles often reach 3~5 years, with costs often reaching hundreds of millions of dollars. Among early-stage candidates, very few successfully enter clinical trials. At its root, there are three major "roadblocks":

First, the target is "tricky," and choosing the biography is a high-stakes gamble.

Many important targets (such as GPCRs and ion channels) are difficult to express and have unstable conformations, making it difficult to elicit effective antibody responses with conventional immunotherapy. What's even more troublesome is that even if antibodies are generated, whether their binding sites (epitopes) have functional blocking activity, are conserved between species, or avoid easily allosteric regions are completely uncontrollable. Traditional selection is like blindfolding the surface of a target, and hitting the surface is pure luck.

Second, affinability and potential for development always overlook one side and the other.

Antibody affinity obtained through initial screening is often only at the micromolar to low nanomolar range. To become a drug, affinity is usually further enhanced (at the nanomolar level or higher), with specific targets varying by target. Traditional methods use error-prone PCR to build mutation libraries, then undergo multiple rounds of selection to mature affinity, with each round taking half a year. What's even more frustrating is that even after finally improving affinity, new problems may arise: hydrophobic plaques in the sequence leading to antibody aggregation and deposition, conformational changes in unstable domains at low pH, or extremely low expression levels in mammalian cells...... These "developability" traps are often exposed late in the project, forcing the entire plan to be scrapped and redone.

Third, humanized transformation is like walking a tightrope from high above.

Mouse antibodies must undergo humanization to reduce the body's antibiotic resistance response. But simply replacing a few skeletal residuals can instantly reset the carefully optimized affinity. How to suppress immunogenicity while maintaining binding activity is a deep area that almost every project must explore.

Facing these challenges that have troubled the biopharmaceutical industry for decades, Matwings Technology's MatwingsVenus™ ™ intelligent device offers a brand-new solution. The MatwingsVenus™ ™ agent is not just a simple computational tool, but a protein R&D platform capable of "conversation." Researchers only need to describe their needs in natural language—for example, "I need an antibody that can bind to X targets and Y epitopes, with affinity at the nanomolar level, and good thermal stability"—MatwingsVenus™ (Xiaowu) can quickly generate high-quality candidate molecular sequences using its large model trained on ™ tens of billions of protein data. More importantly, it can directly design the "blank target" from scratch, meaning it can "customize" entirely new molecules that specifically bind to the target (or even specify epitopes) from the target's 3D structure without any known initial antibody framework. This capability completely breaks the traditional limitation of "antibodies first, then optimization."

In practical applications, the MatwingsVenus™ (Xiaowu™) agent has demonstrated efficiency and accuracy beyond traditional screening methods. For an immune regulatory target that was previously extremely difficult to develop into a drug, this platform generated dozens of entirely new binding molecules with in vitro cell-blocking activity solely through computational design, completing the full process from zero to functional molecules, from design to validation. For projects that already have lead antibodies, MatwingsVenus™ (Xiaowu™) can simultaneously optimize multiple druggability parameters—such as alkaline stability, expression yield, and immunogenicity—while maintaining or even enhancing target affinity. This is not a matter of patching individual parameters, but a systematic upgrade through multi-objective coordination.

Empowered by MatwingsVenus, target-binding antibody development enters a new stage

Target-binding antibodies are the cornerstone of modern precision medicine and carry the hopes of countless patients for more efficient and safer treatments. However, traditional development methods are increasingly unable to meet growing market demands. With the deep integration of artificial intelligence, a new era is arriving.

MatwingsVenus™ (Xiaowu™) from Matwings Technology is making the development of target-binding antibodies faster, simpler, and more efficient. By harnessing the power of AI, it compresses the time and cost from target identification to candidate molecules, resolves conflicts in multi-parameter optimization, and integrates de novo design with experimental validation into a seamless closed-loop process. Against the backdrop of a continuously expanding global antibody drug market and the rapid rise of innovative medicine in China, this empowerment not only signifies a leap in R&D efficiency but also means more innovative therapies can reach patients faster. This is truly the most moving resonance at the intersection of technology and life sciences.